Review article · 2023 · Open access
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Frontiers in Immunology, 14, 1190379 · Published 25 May 2023 · DOI 10.3389/fimmu.2023.1190379
In brief
“Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures” is a 2023 review article by Deep Shah and 2 co-authors, published in Frontiers in Immunology. OpenAlex counts 122 citations as of 21 November 2026, which puts it in the top 8% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 122
- Most cited in
- 2025 (62)
- Field-weighted impact
- 3.66
- References
- 175
- Authors
- 3
Abstract
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient's own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising efficacy, Cytokine Release Syndrome (CRS) is a serious adverse effect and remains a major concern. CRS is a phenomenon of immune hyperactivation that results in excessive cytokine secretion, and if left unchecked, it may lead to multi-organ failure and death. Here we review the pathophysiology of CRS, its occurrence and management in the context of cancer immunotherapy, and the screening approaches that can be used to assess CRS and de-risk drug discovery earlier in the clinical setting with more predictive pre-clinical data. Furthermore, the review also sheds light on the potential immunotherapeutic approaches that can be used to overcome CRS associated with T cell activation.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Shah, D., Soper, B. W., & Shopland, L. S. (2023). Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures. Frontiers in Immunology, 14, 1190379. https://doi.org/10.3389/fimmu.2023.1190379
MLA 9
Shah, Deep, et al. “Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures.” Frontiers in Immunology, vol. 14, 2023, p. 1190379. https://doi.org/10.3389/fimmu.2023.1190379.
Chicago
Shah, Deep, Brian W. Soper, and Lindsay S. Shopland. 2023. “Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures.” Frontiers in Immunology 14: 1190379. https://doi.org/10.3389/fimmu.2023.1190379.
Harvard
Shah, D., Soper, B. W. and Shopland, L. S. (2023) ‘Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures’, Frontiers in Immunology, 14, p. 1190379. doi:10.3389/fimmu.2023.1190379.
IEEE
D. Shah, B. W. Soper, and L. S. Shopland, “Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures,” Frontiers in Immunology, vol. 14, p. 1190379, 2023, doi: 10.3389/fimmu.2023.1190379.
BibTeX
@article{shah2023cytokine,
title = {{Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures}},
author = {Shah, Deep and Soper, Brian W. and Shopland, Lindsay S.},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
pages = {1190379},
doi = {10.3389/fimmu.2023.1190379},
url = {https://doi.org/10.3389/fimmu.2023.1190379}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 2 | |
| 2024 | 27 | |
| 2025 | 62 | |
| 2026 | 31 |
Its field-weighted citation impact is 3.66: it has been cited 3.66 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- cytokine release syndrome
- cancer immunotherapy
- chimeric antigen receptor T cells
- bispecific T-cell engagers
- immune checkpoint inhibitors
- immune hyperactivation
- cytokine production
- multiple organ failure
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Shah, D., Soper, B. W., & Shopland, L. S. (2023). Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures. Frontiers in Immunology, 14, 1190379. https://doi.org/10.3389/fimmu.2023.1190379
How many times has this paper been cited?
122 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Deep Shah, Brian W. Soper, Lindsay S. Shopland.
What is the DOI of this paper?
10.3389/fimmu.2023.1190379, permanently at https://doi.org/10.3389/fimmu.2023.1190379. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.